Pharmaceutical Filtration Market Size, Share & Growth | Report [2033]
The global Pharmaceutical Filtration market size was estimated at USD 12.95 billion in 2023 and is expected to be worth around USD 20.11 billion by 2033, poised to grow at a compound annual growth rate (CAGR) of 4.5% during the forecast period 2024 to 2033.
Pharmaceutical Filtration Market Key Takeaways
Pharmaceutical FiltrationMarket Overview
The pharmaceutical filtration market encompasses a vital segment within the pharmaceutical industry, providing essential solutions to ensure the safety, purity, and efficacy of pharmaceutical products. Filtration processes are integral throughout various stages of drug manufacturing, including raw material purification, final product clarification, and sterile filtration. The market is driven by factors such as stringent regulatory requirements, increasing drug development activities, and the growing demand for biopharmaceuticals and personalized medicine. Technological advancements, particularly in membrane filtration and microfiltration, are enhancing the efficiency and effectiveness of filtration processes, thereby fueling market growth. Additionally, the rise in chronic diseases and the subsequent demand for pharmaceuticals contribute to the market's expansion. The pharmaceutical filtration market is characterized by intense competition among key players striving to innovate and develop novel filtration solutions to meet evolving industry needs. Overall, the market presents significant opportunities for growth and innovation, driven by the continuous quest for higher product quality, regulatory compliance, and operational efficiency within the pharmaceutical manufacturing sector.
Pharmaceutical Filtration Market Growth Factors
The growth of the pharmaceutical filtration market is propelled by several key factors. Firstly, stringent regulations and quality standards imposed by regulatory bodies worldwide necessitate the use of advanced filtration technologies to ensure the safety and efficacy of pharmaceutical products. Additionally, the increasing prevalence of chronic diseases and the subsequent rise in demand for pharmaceuticals drive the need for efficient filtration processes to maintain product purity and integrity. Furthermore, advancements in filtration technologies, such as membrane filtration and microfiltration, enhance the efficiency and effectiveness of pharmaceutical manufacturing processes, thus boosting market growth. Moreover, the growing emphasis on biopharmaceuticals and personalized medicine further fuels the demand for innovative filtration solutions tailored to specific drug formulations and applications. These factors collectively contribute to the expansion of the pharmaceutical filtration market, offering lucrative opportunities for market players and driving continuous innovation in the field.
Pharmaceutical Filtration Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 13.53 Billion |
| Market Size by 2033 | USD 20.11 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 4.5% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product, technique, type, application, scale of operation, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Eaton; Merck KGaA; Amazon Filters Ltd.; Thermo Fisher Scientific Inc; Parker Hannifin Corp; 3M; Sartorius AG.; Graver Technologies; Danaher; Meissner Filtration Products, Inc. |
Product Insights
In the product segment, membrane filters held the largest market share of 29.08% in 2023 and are expected to grow at the fastest CAGR of 9.33% from 2024 to 2033. The dominant share is due to the capability of membrane filters to have a precise and uniform pore size distribution ensuring a consistent filtration quality. This is a key reason for the large market share as it ensures that the final product meets the dedicated specifications and standards.
Furthermore, membrane filters can be made from different forms of materials such as nylon, PTFE, and PVDF allowing them to be versatile in pharmaceutical applications. Additionally, membrane filters adhere to the laid-out cGMP manufacturing practices for pharmaceutical operations. Lastly, product launches and upgradation by market players propel the segmental growth in pharmaceutical filtration. For instance, in November 2022, Alfa Laval launched a multipurpose membrane filtration system for food and pharmaceutical applications at both upstream and downstream levels.
The single-use system is also expected to grow at a significant CAGR of 8.15% during the forecast period. Single-use technologies have had a transformative impact on biopharmaceutical production and development. Some of the critical advantages of using single-use systems are higher flexibility to adjust for volume and demand. Additionally, single-use systems are ideal for small-scale production and research activities.
The growing demand for personalized medicines will help the pharmaceutical filtration market for single-use systems, as they are often manufactured on a smaller scale. For instance, as per Regulatory Affairs Professional Society, the number of personalized medicines under development represents 64% of the total drug development in the World in 2022, which stood at 23% in 2013. Thus, the increasing growth in personalized medicines will propel the single-use systems market for pharmaceutical filtration.
Technique Insights
The microfiltration segment held the largest share of 37.41% in 2023. The dominance of the segment can be attributed to its versatility and overall ability to remove a wide range of impurities from biopharmaceutical products. Additionally, the technique removes particles and impurities without significantly impacting the biological activity or stability of the medium filtered. Furthermore, strategic initiatives are taken by microfiltration systems manufacturers which will continue to aid the segment. For instance, in April 2023, Meissner Corporation announced to invest USD 250 million for a new manufacturing facility in the U.S. for developing advanced microfiltration and therapeutics manufacturing systems.
The nanofiltration segment is estimated to grow at the fastest CAGR of 10.30% during the forecast period. Nanofiltration provides the advantage of selectively removing particles based on size and charge, thereby remitting high usage in separating small molecules and removing endotoxins and pyrogens. Furthermore, the nanofiltration technique requires less energy as compared to ultrafiltration and reverse osmosis which further propels the segment growth.
For instance, as per Springer’s 2019 Article, the two-year average electricity consumed by the nanofiltration technique was 29% less than that of reverse osmosis. Additionally, owing to the growing risk of water pollution by pharmaceutical companies, nanofiltration has been rampantly adopted in commercial spaces to remove caffeine, paracetamol, and naproxen from wastewater. As per MDPI 2022 article, AFC 80 filter can remove 100% of naproxen and caffeine and 96% of paracetamol from water.
Type Insights
The sterile type segment held the largest share of 57.79% of the market in 2023. Sterile filtration acts as a critical step in the manufacturing of most pharmaceutical products, especially injectable drugs, and vaccines, as it ensures the removal of any potential contaminants that could compromise the safety and efficacy of the final product. Furthermore, critical partnerships with leading pharmaceutical manufacturing players allow for the introduction of automation in the sterile form of filtration in pharmaceutical application. For instance, in February 2019, GlaxoSmithKline onboarded a team from Suncombe to automate the system while also protecting the sterile boundary during filter integrity testing.
The non-sterile type of segment is estimated to grow at a CAGR of 7.85% from 2024 to 2033. Non-sterile form of pharmaceutical filtration helps in the removal of particulates or clarification of solutions. Additionally, non-sterile filtration often acts as a pre-filtration level for subsequent sterile filtration. By adding a non-sterile filter in the process, the life of sterile filters can increase.
Moreover, cross-border partnerships pertinent to microbial identification in pharmaceutical, biopharma, and other applications propel the demand for non-sterile forms of filtration. For instance, in May 2023, Charles River Labs announced a partnership with MPL in Austria and Sure Laboratories in the Netherlands. The partnership will provide the latter companies with access to the Charles River database to identify contaminants for both sterile and non-sterile environments of manufacturing.
Application Insights
The final product processing segment held the largest share of 43.55% in 2023. The dominant share of the market is due to the criticality of its role in ensuring safety and efficacy in the final product by removing any form of impurity or contaminants allowing it to comply with the regulatory guidelines. Additionally, the regulatory guidelines from the U.S. FDA, EMA, Japanese Ministry of Health, and others have strict guidelines for biologics and vaccine manufacturing requiring multiple steps in the final product processing for quality, purity, and safety, failing to comply which can result in termination of approval or the credibility of the manufacturing facility.
For example, in October 2020, the U.S. FDA sent a warning letter to AuroLIife Pharma, as there were significant violations pertinent to cGMP practice for finished pharmaceuticals, which conformed to non-adherence to final product processing. As their practices did not follow minimum safety criteria, products sold by the firm were declared adulterated.
The cell separation segment is estimated to grow at a CAGR of 8.14% during 2024-2033. Cell separation growth can be attributed to the rapidly growing demand for cell therapies as a cure for genetic conditions and other health malignancies. CAR-T therapies and stem cell therapies are gaining the utmost market traction owing to the rising cases of cancer, autoimmune diseases, and others.
The following therapies use pharmaceutical filtration techniques such as tangential flow filtration (TFF) to separate cells from culture media efficiently without damaging cells in the separation process. Moreover, regulatory approvals for cell therapies have extrapolated the demand for pharmaceutical filtration. For instance, on February 28, 2022, Ciltacabtagene autoleucel, or known as Carvykti CAR-T therapy was approved by the U.S. FDA, specifically for patients suffering from multiple myeloma, relapsed or refractory. Such approvals are expected to propel the market of pharmaceutical filtration.
Scale of Operation Insights
The manufacturing scale of operations held a dominant share of 67.95% in the year 2023. Manufacturing operations dominated the segment owing to the magnitude of operations, and the regulatory requirements pertinent to such operations. Filtration processes within manufacturing operations ensure drug safety, purity, and efficacy. Furthermore, the quality of the final product is directly related to the processes of pharmaceutical filtration in drug manufacturing.
Additionally, various regulatory norms propel manufacturers to adhere to the practices of filtration. For example, the U.S. FDA requires strict adherence to the cGMP practices which also includes the appropriate filtration techniques. Lastly, the demand for large-molecule drugs has risen considerably over the years by patients, and manufacturers require extensive pharmaceutical filtration for large-molecule drugs as they are more complex.
To maintain the supply for such demand, various CDMOs are being roped in for manufacturing of large molecule drugs which is further propelling the market for pharmaceutical filtration. For instance, on August 2022, Charles River Laboratories became the CDMO operating in North America to receive EMA approval in the form of Good Manufacturing Practice (GMP) to produce allogeneic cell therapy products, thereby, increasing the demand for pharmaceutical filtration products.
The research and development scale segment is estimated to grow at the fastest CAGR of 11.41% during the forecast period. The organizations operating in the R&D sector provide a key role in driving overall drug innovation and advancing pharmaceutical practices to improve the level of patient care. Furthermore, active research support from academic institutions propels the usage of pharmaceutical filtration products. For instance, as per Clinical Trial. Gov. in May 2023, Harvard Medical School is conducting a trial to understand and formulate biologics treatment for rheumatoid arthritis.
Due to following advancements in medicinal treatment, single-use filtration products will increase. Moreover, biologics and biosimilars are being actively researched which will give the segment a major boost. As per Pharmaceutical Research and Manufacturers of America (PhRMA) 2023, nearly 907 biologics are being developed within the U.S. to target more than 100 diseases. Owing to the magnitude of research activities for biologics, the demand for filtration products will propel during the forecast period.
Regional Insights
In 2023, North America dominated the industry with a revenue share of 45.19%. This is attributed to several factors, including the presence of large dominant pharmaceutical and biopharmaceutical companies including Gilead Sciences, Inc.; Pfizer Inc.; Johnson & Johnson Services, Inc.; and Amgen Inc.
.webp "Pharmaceutical Filtration Market Share, By Region, 2023 (%)")
Well-developed healthcare infrastructure and accessibility to advanced products in this region have fueled the regional growth. Furthermore, the healthcare coverage policies in the U.S. allows the patients to get the right treatment, which further propels the biopharma manufacturing companies and academic institutions to look for advanced drugs. For instance, as per Congressional Research Service 2021, nearly 91.4% of the American population in medically insured.
Asia Pacific is anticipated to register the highest CAGR of 14.48% during the forecast period. It is owing to rampant growth in the overall biopharmaceutical manufacturing activities in emerging economies such as India and China. For instance, as per BioProcessing International Article 2022, China and India rank second and third in pharmaceutical production capacities. Furthermore, biosimilar growth and specialty pharmaceuticals will further fuel the growth of the market for pharmaceutical filtration in drug manufacturing practices.
Pharmaceutical Filtration Market Top Key Companies:
Pharmaceutical Filtration Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Pharmaceutical Filtration market.
By Product
By Technique
By Type
By Application
By Scale of Operation
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers